Literature DB >> 21132028

Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD.

S Thiant1, M Labalette, J Trauet, V Coiteux, E de Berranger, J-P Dessaint, I Yakoub-Agha.   

Abstract

To assess the impact of homeostatic expansion on the occurrence of acute GVHD after reduced intensity conditioning (RIC) transplantation, systemic levels of IL-7 and IL-15 and expression of their specific receptor chains were prospectively investigated in 45 fully HLA-matched allograft recipients. IL-7 and IL-15 levels peaked at four- to fivefold over pre-conditioning values. IL-7 levels were inversely correlated to absolute T-cell counts. Peak IL-15 levels positively correlated to concurrent CRP levels, but normalized earlier than IL-7. These results indicate that the kinetic course of IL-7 depends mainly on initiation of T-cell recovery, while IL-15 depends more on peri-transplant inflammation after RIC. Longer duration of the rise in IL-7 levels was associated with preservation of a normal CD4/CD8 ratio. In all, 16 (35%) patients developed grade 2-4 acute GVHD at a median of 42 days post graft, preceded by higher IL-7 levels and more downregulation of IL-7 receptor α chain on CD4(+) T cells than in patients without acute GVHD, suggesting enhanced homeostatic expansion. In multivariate analysis, IL-7 level measured on day +30 was the foremost predictive factor for grade 2-4 acute GVHD (P=0.002). Measurement of IL-7 level after RIC transplantation might help predict risk of subsequent acute GvHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132028     DOI: 10.1038/bmt.2010.300

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Authors:  Yvonne Suessmuth; Rithun Mukherjee; Benjamin Watkins; Divya T Koura; Knut Finstermeier; Cindy Desmarais; Linda Stempora; John T Horan; Amelia Langston; Muna Qayed; Hanna J Khoury; Audrey Grizzle; Jennifer A Cheeseman; Jason A Conger; Jennifer Robertson; Aneesah Garrett; Allan D Kirk; Edmund K Waller; Bruce R Blazar; Aneesh K Mehta; Harlan S Robins; Leslie S Kean
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

Review 2.  The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.

Authors:  Alaa M Ali; John F DiPersio; Mark A Schroeder
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-05       Impact factor: 5.742

Review 3.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

4.  Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation.

Authors:  Isabel Barao; Maite Alvarez; Doug Redelman; Jonathan M Weiss; John R Ortaldo; Robert H Wiltrout; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-08       Impact factor: 5.742

5.  Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD.

Authors:  Anne-Kathrin Hechinger; Benjamin A H Smith; Ryan Flynn; Kathrin Hanke; Cameron McDonald-Hyman; Patricia A Taylor; Dietmar Pfeifer; Björn Hackanson; Franziska Leonhardt; Gabriele Prinz; Heide Dierbach; Annette Schmitt-Graeff; Jiri Kovarik; Bruce R Blazar; Robert Zeiser
Journal:  Blood       Date:  2014-10-28       Impact factor: 22.113

6.  BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.

Authors:  Evelyn Ullrich; Benjamin Abendroth; Johanna Rothamer; Carina Huber; Maike Büttner-Herold; Vera Buchele; Tina Vogler; Thomas Longerich; Sebastian Zundler; Simon Völkl; Andreas Beilhack; Stefan Rose-John; Stefan Wirtz; Georg F Weber; Sakhila Ghimire; Marina Kreutz; Ernst Holler; Andreas Mackensen; Markus F Neurath; Kai Hildner
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

Review 7.  Advances in predicting acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; John E Levine
Journal:  Br J Haematol       Date:  2012-12-04       Impact factor: 6.998

8.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

9.  Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.

Authors:  Ken-ichi Matsuoka; John Koreth; Haesook T Kim; Gregory Bascug; Sean McDonough; Yutaka Kawano; Kazuyuki Murase; Corey Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Sci Transl Med       Date:  2013-04-03       Impact factor: 17.956

Review 10.  Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.

Authors:  Sophie Paczesny; Christine Duncan; David Jacobsohn; Robert Krance; Kathryn Leung; Paul Carpenter; Catherine Bollard; Jamie Renbarger; Kenneth Cooke
Journal:  Proteomics Clin Appl       Date:  2014-10-30       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.